Selenium inhibits growth of trastuzumab-resistant human breast cancer cells via downregulation of Akt and beclin-1

The response rate to treatment with trastuzumab (Tz), a recombinant humanized anti-HER2 monoclonal antibody, is only 12–34% despite demonstrated effectiveness on improving the survival of patients with HER2-positive breast cancers. Selenium has an antitumor effect against cancer cells and can play a...

Descripción completa

Detalles Bibliográficos
Autores principales: Woo, Joohyun, Kim, Jong Bin, Cho, Taeeun, Yoo, Eun Hye, Moon, Byung-In, Kwon, Hyungju, Lim, Woosung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443054/
https://www.ncbi.nlm.nih.gov/pubmed/34525121
http://dx.doi.org/10.1371/journal.pone.0257298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443054/
https://www.ncbi.nlm.nih.gov/pubmed/34525121
http://dx.doi.org/10.1371/journal.pone.0257298

Ejemplares similares